Last $163.21 USD
Change Today +0.32 / 0.20%
Volume 724.3K
ALXN On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $185.43
52 Week Low
07/12/13 - $100.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

1,774 Employees
Last Reported Date: 02/10/14
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Treasure...
Total Annual Compensation: $1.2M
Co-Founder, Chief Global Operations Officer a...
Total Annual Compensation: $607.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $610.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion and Cincinnati Children's Hospital Establish Rare Disease Innovation Fund

Alexion Pharmaceuticals and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. This collaboration leverages the collective expertise of a leading pediatric hospital with a biopharmaceutical company, the groups noted in a media release. Under the terms of the agreement, the group noted that Alexion will have the opportunity to fund selected research programs through the Alexion Rare Disease Innovation Fund. Following completion of the funded research programs, Alexion will have an exclusive option to enter into a licensing agreement for these programs.

Alexion Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM

Alexion Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Alexion Pharmaceuticals Receives Orphan Drug Designation to Soliris (Eculizumab) for the Treatment of Patients with Myasthenia Gravis from U.S. Food and Drug Administration

Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan drug designation to Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis, a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body. Soliris is a first-in-class terminal complement inhibitor and is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is not approved in any country to treat MG. Alexion is enrolling patients in a multinational, placebo-controlled registration trial of eculizumab in patients with refractory generalized MG.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $163.21 USD +0.32

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Intrexon Corp $25.06 USD +0.24
MorphoSys AG €68.71 EUR +0.63
Regeneron Pharmaceuticals Inc $316.11 USD +1.62
United Therapeutics Corp $93.26 USD +0.31
Vertex Pharmaceuticals Inc $99.07 USD +1.25
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXN Industry Range
Price/Earnings 99.1x
Price/Sales 18.1x
Price/Book 12.0x
Price/Cash Flow 97.7x
TEV/Sales 17.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at